Download MendeleyDiscovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection.
Bu, F., Ye, G., Morsheimer, K., Mendoza, A., Turner-Hubbard, H., Herbst, M., Spiller, B., Wadzinski, B.E., Eaton, B., Anantpadma, M., Yang, G., Liu, B., Davey, R., Li, F.(2024) PLoS Pathog 20: e1012817-e1012817
- PubMed: 39715280
- DOI: https://doi.org/10.1371/journal.ppat.1012817
- Primary Citation of Related Structures:
9BSU, 9BSV - PubMed Abstract:
The Ebola filovirus (EBOV) poses a serious threat to global health and national security. Nanobodies, a type of single-domain antibody, have demonstrated promising therapeutic potential. We identified two anti-EBOV nanobodies, Nanosota-EB1 and Nanosota-EB2, which specifically target the EBOV glycoprotein (GP). Cryo-EM and biochemical data revealed that Nanosota-EB1 binds to the glycan cap of GP1, preventing its protease cleavage, while Nanosota-EB2 binds to critical membrane-fusion elements in GP2, stabilizing it in the pre-fusion state. Nanosota-EB2 is a potent neutralizer of EBOV infection in vitro and offers excellent protection in a mouse model of EBOV challenge, while Nanosota-EB1 provides moderate neutralization and protection. Nanosota-EB1 and Nanosota-EB2 are the first nanobodies shown to inhibit authentic EBOV. Combined with our newly developed structure-guided in vitro evolution approach, they lay the foundation for nanobody-based therapies against EBOV and other viruses within the ebolavirus genus.
- Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota, United States of America.
Organizational Affiliation:
